NYSE — Healthcare: Manufacturing, Drug Manufacturers - General: Pharmaceutical Preparations
www.pfizer.comPfizer will present data on breakthrough cancer medicines at the ASCO Annual Meeting from May 30 to June 3, showcasing over 60 abstracts across various cancer types.
conference talkThe AGMT registry study for metastatic breast cancer in Austria is expected to complete on June 1, 2025. The registry aims to document disease progression, treatment strategies, and outcomes in a real-world population, including analysis of survival data and the influence of gender and tumour subtype on therapy. The study, sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie, is designed to inform future treatment approaches for metastatic breast cancer in Austria. Pfizer (PFE) is listed as a related company, though not as the primary sponsor.
trial completionPfizer's board declared a quarterly cash dividend of $0.43 per share, payable on June 13, 2025, marking the 346th consecutive quarterly dividend.
dividendSeagen Inc., a wholly owned subsidiary of Pfizer, is expected to complete its multi-country chart review cohort study (NCT05902494) on HER2-positive and locally advanced or metastatic urothelial cancer on July 14, 2025. The observational study aims to analyze medical records of 350 patients to better understand the impact of HER2 expression on treatment choices and outcomes in unresectable or metastatic urothelial cancer. The trial is currently recruiting participants.
trial completionThe Phase 1 clinical trial evaluating PF-08046049/SGN-BB228, an investigational therapy for advanced melanoma and other solid tumors, is expected to complete on October 17, 2025. The study, sponsored by Seagen Inc., a wholly owned subsidiary of Pfizer, is assessing the safety, tolerability, and preliminary efficacy of the drug in patients with difficult-to-treat or metastatic solid tumors. PF-08046049/SGN-BB228 is a novel agent under early-stage development for oncology indications.
trial completionNiKang Therapeutics is conducting a Phase 2 trial of NKT2152 in combination with palbociclib and sasanlimab for patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have progressed after prior VEGF/VEGFR and immune checkpoint inhibitor therapies. The study, which began in July 2023, is expected to complete on June 1, 2026. NKT2152 is a HIF2α inhibitor, palbociclib is a CDK4/6 inhibitor, and sasanlimab is a PD-1 inhibitor. Pfizer is involved as a collaborator due to its interest in palbociclib and sasanlimab.
trial completionA Phase 2 clinical trial (NCT02960022) for subjects with prostate cancer previously treated with enzalutamide is expected to complete on July 31, 2026. The study, sponsored by Astellas Pharma Global Development, Inc., involves continued treatment regimens and regular monitoring for adverse events. The trial aims to assess long-term safety and outcomes in this patient population. Pfizer is a collaborator on the study.
trial completionThe phase 2/3 clinical trial NCT06218069, sponsored by Radboud University Medical Center, is expected to complete on March 1, 2027. The study evaluates disease-free survival in patients receiving a single subcutaneous dose of Pfizer's anti-PD1 antibody sasanlimab (PF-06801591) in a neo-adjuvant setting, with or without radiation, followed by surgery. The trial also uses the radiolabeled imaging tracer [89Zr]Zr-crefmirlimab berdoxam to visualize CD8+ T-cells. Enrollment is set at 20 participants. Sasanlimab is an investigational immunotherapy targeting PD-1, relevant for oncology indications.
trial completionPfizer is conducting a Phase 3 clinical trial (NCT04821622) evaluating Talazoparib in combination with Enzalutamide for men with metastatic castration-sensitive prostate cancer (mCSPC) harboring DDR gene mutations. The study, which began in May 2021 and enrolled approximately 599 participants, is expected to complete on August 7, 2027. Talazoparib is a PARP inhibitor, and Enzalutamide is an androgen receptor inhibitor, both used in prostate cancer treatment. The trial's outcome may impact future treatment options for this patient population.
trial completionThe clinical trial for PF-08046054/SGN-PDL1V, sponsored by Seagen Inc., is expected to complete on September 4, 2027. This trial assesses the safety and efficacy of the drug in patients with advanced solid tumors, including those that are metastatic or unresectable. The study involves multiple parts to determine the appropriate dosage and evaluate the drug's effectiveness, both alone and in combination with pembrolizumab.
trial completion